BioNTech Highlights First Global Data For Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination

BNTX•2026-08-20

Company highlights lung cancer pipeline updates

BioNTech SE said it is highlighting late-stage lung cancer pipeline momentum and first global data for the pumitamig/elfetabart drozuntecan novel-novel combination at WCLC 2026.

Presents first data for PD-(L)1×VEGF bispecific immunomodulator plus ADC in lung cancer
Pipeline includes monotherapies, standard of care combinations, and novel-novel regimens for lung cancer
Advancing over 16 ongoing lung cancer trials including five phase 3 trials
To present updated overall survival data for gotistobart in advanced squamous NSCLC

BioNTech Highlights First Global Data For Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination

Company highlights lung cancer pipeline updates

Related News

Ultragenyx rises after securing FDA nod for rare metabolic disorder gene therapy

Campbell's Co <CPB.O>: UBS Raises Target Price to $18 From $17

Zoom Communications, Inc. <ZM.O>: UBS Raises Target Price to $115 From $105

Advance Auto Parts Q2 Adjusted EPS USD 1.03 Vs. IBES Estimate USD 0.8

PFG names Matthew Flanigan lead independent director effective after 2026 annual meeting